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Clinical PerspectiveWhat Is New?Among patients with low CHA~2~DS~2~‐VASc scores, the majority were treated with systemic oral anticoagulation.Aspirin use was high among patients with low CHA~2~DS~2~‐VASc scores, even in those already treated with oral anticoagulation at baseline.What Are the Clinical Implications?The absolute risk of death and stroke/transient ischemic attack was low among both males and females CHA~2~DS~2~VASc=0‐1 as well as among females with a CHA~2~DS~2~VASc score=2.

 {#jah33418-sec-0009}

Atrial fibrillation (AF) is associated with a significantly increased risk of stroke and systemic embolism, which varies based upon the presence of additional risk factors.[1](#jah33418-bib-0001){ref-type="ref"}, [2](#jah33418-bib-0002){ref-type="ref"}, [3](#jah33418-bib-0003){ref-type="ref"} Patients with AF‐related strokes have worse prognosis and higher risk of recurrent events compared with non‐AF‐related strokes.[4](#jah33418-bib-0004){ref-type="ref"} Prevention of stroke and systemic embolism is facilitated through the use of antithrombotic agents, principally oral vitamin K‐antagonists or direct OACs (oral anticoagulants).[5](#jah33418-bib-0005){ref-type="ref"}, [6](#jah33418-bib-0006){ref-type="ref"}, [7](#jah33418-bib-0007){ref-type="ref"}, [8](#jah33418-bib-0008){ref-type="ref"} The CHA~2~DS~2~VASc score is a risk stratification tool used to estimate the risk of stroke in patients with nonvalvular AF[9](#jah33418-bib-0009){ref-type="ref"} and is recommended for use in the guidelines of many international cardiovascular medicine societies.[10](#jah33418-bib-0010){ref-type="ref"}, [11](#jah33418-bib-0011){ref-type="ref"}

Differences exist in the treatment recommendations and administration of oral anticoagulation for "low risk" patients across various guidelines. At present the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines for the management of AF recommend that patients with a CHA~2~DS~2~VASc score=1 can be treated with no therapy, aspirin only, or oral anticoagulation (Class IIb, Level of Evidence C); for patients with a CHA~2~DS~2~VASc score=0, antiplatelet or OAC therapy can be omitted (class IIa).[10](#jah33418-bib-0010){ref-type="ref"} The European guidelines favor treatment in patients with 1 nonsex risk factor.[12](#jah33418-bib-0012){ref-type="ref"}, [13](#jah33418-bib-0013){ref-type="ref"} The true absolute risk and optimal treatment in these patients, including females with a CHA~2~DS~2~VASc score=2, is controversial and not entirely known.[14](#jah33418-bib-0014){ref-type="ref"} Accordingly, we used the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I and II to define thromboembolic event rates in "low"‐risk patients in contemporary community practice and to describe the antiplatelet and anticoagulant treatment patterns of patients with a CHA~2~DS~2~VASc score=0, 1 (by definition) and females with a CHA~2~DS~2~VASc=2 (females with 1 additional stroke risk factor).

Methods {#jah33418-sec-0010}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Population {#jah33418-sec-0011}
----------------

The rationale and design of the ORBIT‐AF and ORBIT‐AF II registries have been previously described.[15](#jah33418-bib-0015){ref-type="ref"}, [16](#jah33418-bib-0016){ref-type="ref"} Both ORBIT‐AF and OBRIT‐AF II are prospective, nationwide multicenter registries of patients with AF across the United States managed by a variety of providers including internists, general cardiologists, and electrophysiologists. Briefly, eligible patients included those 18 years of age or older, with electrocardiographically documented AF, who were able to provide written informed consent, and to comply with regularly scheduled follow‐up visits. Patients with atrial flutter only and those with reversible causes of AF (eg, pulmonary embolism) were excluded from participation. As ORBIT‐AF and ORBIT‐AF II are observational registries, all treatment decisions were left to the discretion of the individual treating physicians in accordance with practice guidelines, recommendations, and local standards of care. Following initial enrollment, longitudinal information was collected during healthcare visits at ≈6‐month intervals up to 36 months (6‐month intervals up to 24 months for ORBIT‐AF II). These follow‐up data included information on hospitalizations, bleeding events, quality of life, procedures, and medical therapies. ORBIT‐AF I included patients with AF that was not thought to be attributable to a reversible cause. By design, ORBIT‐AF II also excluded patients with reversible causes of AF (eg, pulmonary embolism). Enrollment in ORBIT‐AF II was geared toward capturing a contemporary cohort of patients with AF treated with direct OACs (dabigatran, apixaban, rivaroxaban, and edoxaban); only patients with either (1) new‐onset AF within the previous 6 months and/or (2) patients with AF recently switched to a direct OAC within 3 months were eligible.

For the purpose of this analysis, we identified patients at "low" risk of thromboembolic stroke based upon guideline recommendations, including those with a CHA~2~DS~2~VASc score of zero, 1 (by definition), and females with a CHA~2~DS~2~VASc score=2, with our comparison group being patients with a CHA~2~DS~2~VASc ≥2 (excluding females with CHA~2~DS~2~VASc score=2).[10](#jah33418-bib-0010){ref-type="ref"}, [12](#jah33418-bib-0012){ref-type="ref"} Between June 29, 2010 and August 9, 2011, 10 137 patients were enrolled in the ORBIT‐AF registry from 176 sites across the United States. From this we excluded 388 patients because of incomplete follow‐up or death without any follow‐up (postbaseline). This yielded a final study population of 9749 from which CHA~2~DS~2~VASc risk scores were calculated. Among these 9749 patients, at enrollment 212 (2.1%) had a CHA~2~DS~2~VASc score of 0, 659 (6.8%) had a CHA~2~DS~2~VASc score of 1, and 267 (2.7%) females had a CHA~2~DS~2~VASc score=2. Between February 20, 2013 and June 8, 2016, 11 603 patients were enrolled in the ORBIT‐AF II registry from 242 sites across the United States. From this we excluded 2954 because of incomplete follow‐up or death without any follow‐up. This yielded a final study population of 8649. Among these 8649 patients, at enrollment 329 (4.0%) had a CHA~2~DS~2~VASc score of 0, 930 (11.0%) had a CHA~2~DS~2~VASc score of 1, and 403 (4.7%) females had a CHA~2~DS~2~VASc score=2.

Statistical Analysis {#jah33418-sec-0012}
--------------------

We compared baseline and AF characteristics of patients between 4 groups: CHA~2~DS~2~VASc=0, CHA~2~DS~2~VASc=1, females with a CHA~2~DS~2~VASc score=2, and all patients with a CHA~2~DS~2~VASc ≥2 (excluding females with a CHA~2~DS~2~VASc score=2). Continuous variables were presented as medians (interquartile range) and categorical variables will be presented as proportions. To compare characteristics between groups, we used the Kruskal‐Wallis test for continuous variables and the χ^2^ test for categorical variables. In order to describe the major outcomes for patients with CHA~2~DS~2~VASc=0, CHA~2~DS~2~VASc=1, and females with a CHA~2~DS~2~VASc score=2, we calculated the total number of events and number per 100 patient‐years for the overall group and 3 stratified groups. In addition, adjusted and unadjusted rates of major outcomes alone and major outcomes stratified by OAC use were performed using Cox proportional hazard modeling using Firth\'s penalized likelihood method, respectively. For the adjusted analysis, the model was composed of several covariates including prior atrioventricular node/HIS bundle ablation, AF type, age, anemia, prior antiarrhythmic drug use, prior percutaneous coronary intervention, BMI, cancer, cognitive impairment/dementia, chronic obstructive pulmonary disease, history of coronary artery disease, diabetes mellitus, diastolic blood pressure, systolic blood pressure, dialysis, eGFR, European Heart Rhythm Association score, sex, New York Heart Association functional status, frailty, height, history of drug abuse, history of gastrointestinal bleed, hyperlipidemia, hypertension, insurance status, intraventricular conduction, hematocrit, left atrial diameter type, liver disease, level of education, left ventricular ejection fraction type, obstructive sleep apnea, prior myocardial infarction, family history of AF, significant valvular disease, heart rate, peripheral vascular disease, rhythm control, smoking status, provider specialty, history of stroke/transient ischemic attack (TIA), and weight. For the unadjusted analysis, interaction testing was performed to test the association between the outcome and therapy within each CHA~2~DS~2~VASc group.

The ORBIT‐AF and ORBIT‐AF II registries were approved by the Duke Institutional Review Board, and all participating sites obtained institutional review board approval pursuant to local requirements. All subjects provided written, informed consent. All *P* values presented are 2 sided. All statistical analyses were performed at the Duke Clinical Research Institute using SAS software (version 9.3; SAS Institute, Cary, NC).

Results {#jah33418-sec-0013}
=======

Patient and AF Characteristics {#jah33418-sec-0014}
------------------------------

In the overall cohort (ORBIT AF I & II) CHA~2~DS~2~VASc 0‐1 or females with a CHA~2~DS~2~VASc score=2 accounted for 15.2% (N=2820/18 398) of the overall population (Table [1](#jah33418-tbl-0001){ref-type="table"}). The majority of patients with a CHA~2~DS~2~‐VASc score=0 and 1 were 50 years and older (Figure [S1](#jah33418-sup-0001){ref-type="supplementary-material"} and Figure [1](#jah33418-fig-0001){ref-type="fig"}), respectively. Compared with patients with a CHA~2~DS~2~VASc score ≥2 (excluding females with an additional stroke risk factor), patients with a CHA~2~DS~2~VASc score=0, CHA~2~DS~2~VASc score=1, and females with a CHA~2~DS~2~VASc score=2 were younger, more likely to have paroxysmal AF, more likely to be treated with a rhythm control strategy including the use of antiarrhythmic drugs and catheter ablation of AF, more likely to have disabling or severe symptoms associated with AF, and less likely to have risk factors associated with AF such as hypertension, diabetes mellitus, or coronary artery disease (Table [1](#jah33418-tbl-0001){ref-type="table"}).

###### 

Baseline Characteristics Across CHA~2~DS~2~VASc Groups

                                 CHA~2~DS~2~VASc=0 (N=541)   CHA~2~DS~2~VASc=1 (N=1589)   Females With an Additional Risk Factor (N=670)   CHA~2~DS~2~VASc≥2 (N=15 598)   *P* Value
  ------------------------------ --------------------------- ---------------------------- ------------------------------------------------ ------------------------------ -----------
  Age, y                         55 (48--60)                 60 (53--63)                  63 (59--68)                                      75 (68--82)                    \<0.0001
  Male                           100                         84                           0                                                56                             \<0.0001
  Race                                                                                                                                                                    
  White                          88                          88                           88                                               88                             0.04
  Black                          4.4                         4.5                          4.5                                              4.9                            
  Hispanic                       4.8                         4.1                          5.4                                              4.8                            
  Medical history                                                                                                                                                         
  Hypertension                   0                           54                           51                                               89                             \<0.0001
  Current smoker                 18                          24                           19                                               22                             \<0.0001
  Cancer                         8.0                         11                           13                                               24                             \<0.0001
  Coronary artery disease        0                           3.0                          3.0                                              37                             \<0.0001
  COPD                           3.1                         5.0                          7.3                                              15                             \<0.0001
  Obstructive sleep apnea        20                          21                           15                                               18                             0.004
  Significant valvular disease   5.2                         9.0                          12                                               22                             \<0.0001
  Heart failure (class III/IV)   0                           1.1                          1.2                                              6.4                            \<0.0001
  Diabetes mellitus              0                           3.0                          4.0                                              33                             \<0.0001
  BMI, kg/m^2^                   29 (26--33)                 31 (27--36)                  31 (26--37)                                      29 (25--34)                    \<0.0001
  Systolic blood pressure        120 (111--128)              123 (114--134)               125 (116--138)                                   127 (118--139)                 \<0.0001
  Diastolic blood pressure       78 (70--82)                 78 (70--83)                  76 (70--82)                                      72 (66--80)                    \<0.0001
  Serum creatinine, mg/dL        1.0 (0.9--1.1)              1.0 (0.8--1.1)               0.8 (0.7--0.9)                                   1.0 (0.9--1.3)                 \<0.0001
  LVEF (Normal)                  81                          76                           83                                               70                             \<0.0001
  AF type                                                                                                                                                                 
  First detected                 36                          33                           33                                               25                             \<0.0001
  Paroxysmal                     46                          44                           52                                               42                             
  Persistent                     14                          16                           11                                               14                             
  Permanent                      4.0                         7.3                          5.0                                              19                             
  EHRA score                                                                                                                                                              
  No symptoms                    29                          32                           27                                               37                             \<0.0001
  Mild                           50                          47                           50                                               45                             
  Severe                         20                          19                           20                                               17                             
  Disabling                      2.0                         3.0                          3.0                                              2.0                            
  AF management strategy                                                                                                                                                  
  Rate control                   46                          55                           57                                               67                             \<0.0001
  Rhythm control                 54                          45                           43                                               33                             
  Prior cardioversions           36                          33                           25                                               26                             \<0.0001
  Prior AAD                      39                          39                           35                                               36                             \<0.0001
  Catheter ablation of AF        17                          10                           9.0                                              4.4                            \<0.0001
  AV node ablation               0.2                         1.0                          1.3                                              1.5                            0.002
  ATRIA score                    0                           1.0 (0.0, 1.0)               1.0 (0.0, 1.0)                                   3.0 (1.0, 4.0)                 \<0.0001

Values presented as percentages or median (interquartile range). AAD indicates antiarrhythmic drug; AF, atrial fibrillation; ATRIA, anticoagulation and risk factors in atrial fibrillation; AV, atrioventricular; BMI, body mass index; BPM, beats per minute; CHA~2~DS~2~VASc, Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus, Stroke, Vascular Disease, Age (65--74 years), Sex; COPD, chronic obstructive pulmonary disease; creatinine clearance (mg/min per 1.73 m^2^) calculated by Cockcroft‐Gault formula; EHRA, European Heart Rhythm Association; LVEF, left ventricular ejection fraction.

![Age distribution among patients with a CHA~2~DS~2~‐VASc score of 1.](JAH3-7-e008764-g001){#jah33418-fig-0001}

Stroke Prevention Therapy {#jah33418-sec-0015}
-------------------------

The treatment strategies across the low‐risk groups are shown in (Table [2](#jah33418-tbl-0002){ref-type="table"}). OAC use differed significantly across all groups, with increasing use of any oral anticoagulant in parallel with increasing CHA~2~DS~2~VASc risk score (Figure [2](#jah33418-fig-0002){ref-type="fig"}). Even among patients with a CHA~2~DS~2~VASc=0, OAC use was used in almost two thirds of patients. Aspirin use was significantly different at baseline, with the highest use in patients with CHA~2~DS~2~VASc=0 (40.9%), compared with CHA~2~DS~2~VASc=1 (37.6%), females with a CHA~2~DS~2~VASc=2 (32.7%), and patients with a CHA~2~DS~2~VASc score ≥2 (38.6%), (*P*=0.01). The use of antiplatelet therapy with a P2Y~12~ inhibitor, either as single therapy or combined with aspirin, was significantly higher in patients with a CHA~2~DS~2~VASc score ≥2. Apixaban use was significantly higher in females with a CHA~2~DS~2~VASc=2, compared with patients with CHA~2~DS~2~VASc=0,1 and ≥2, respectively (16.4% vs. 10.5% vs. 12.0% vs. 13.4%, *P*\<0.0001); dabigatran and rivaroxban use were not significantly different across low‐risk groups. Patients with a CHA~2~DS~2~VASc=0 were more likely to not be treated with any antithrombotic therapy, although the percentage of patients not treated with any antithrombotic therapy decreased with increasing CHA~2~DS~2~VASc score.

###### 

Antiplatelet and Anticoagulant Treatment Across CHA~2~DS~2~VASc Groups

                                    CHA~2~DS~2~VASc=0 (N=541)   CHA~2~DS~2~VASc=1 (N=1589)   Females With an Additional Risk Factor (N=670)   CHA~2~DS~2~VASc≥2 (N=15 598)   *P* Value
  --------------------------------- --------------------------- ---------------------------- ------------------------------------------------ ------------------------------ -----------
  No antiplatelet or AC             51 (9.4%)                   114 (7.2%)                   49 (7.3%)                                        577 (3.7%)                     \<0.0001
  Aspirin at baseline               221 (40.9%)                 598 (37.6%)                  219 (32.7%)                                      6021 (38.6%)                   0.01
  Aspirin and P2Y~12~ at baseline   1 (0.2%)                    13 (0.8%)                    1 (0.1%)                                         597 (3.8%)                     \<0.0001
  P2Y~12~ at baseline               2 (0.4%)                    21 (1.3%)                    5 (0.7%)                                         1063 (6.8%)                    \<0.0001
  Any oral anticoagulant            326 (60.3%)                 1111 (69.9%)                 485 (72.4%)                                      13 137 (84.2%)                 \<0.0001
  Current warfarin use              105 (19.4%)                 438 (27.6%)                  172 (25.7%)                                      7585 (48.6%)                   \<0.0001
  Dabigatran at baseline            32 (5.9%)                   106 (6.7%)                   36 (5.4%)                                        785 (5.0%)                     0.04
  Rivaroxaban at baseline           132 (24.4%)                 377 (23.7%)                  167 (24.9%)                                      2702 (17.3%)                   0.50
  Apixaban at baseline              57 (10.5%)                  190 (12.0%)                  110 (16.4%)                                      2087 (13.4%)                   \<0.0001
  Aspirin and AC at baseline        58 (10.7%)                  238 (15.0%)                  86 (12.8%)                                       4276 (27.4%)                   \<0.0001
  P2Y~12~ and AC at baseline        0 (0.0%)                    5 (0.3%)                     1 (0.1%)                                         624 (4.0%)                     \<0.0001

AC indicates oral anticoagulants including: warfarin, dabigatran, rivaroxaban, and apixaban; CHA~2~DS~2~VASc, Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus, Stroke, Vascular Disease, Age (65--74 years), Sex; P2Y~12~; includes clopidogrel, prasugrel, and ticagrelor.

![Antiplatelet and antithrombotic treatment strategies in the combined ORBIT AF and ORBIT AF II cohorts. OAC indicates oral anticoagulant.](JAH3-7-e008764-g002){#jah33418-fig-0002}

Outcomes {#jah33418-sec-0016}
--------

Event rates and adjusted analyses in the combined cohort are shown in Table [3](#jah33418-tbl-0003){ref-type="table"}. Thromboembolic event rates (TIA, stroke, or systemic embolism) were zero per 100 patient‐years for CHA~2~DS~2~VASc=0, 0.8 per 100 patient‐years in CHA~2~DS~2~VASc=1, 0.8 per 100 patient‐years in females with a CHA~2~DS~2~VASc score=2, and 1.7 per 100 patient‐years in the CHA~2~DS~2~VASc ≥2 group (*P*=0.17). All‐cause mortality was low among low‐risk CHA~2~DS~2~VASc groups but highest among patients with a CHA~2~DS~2~VASc ≥2 (5.7 per 100 patient‐years) (*P*=0.45). In addition, females with a CHA~2~DS~2~VASc score=2 had the highest rates of all‐cause mortality, cardiovascular death, first major bleeding, first bleeding hospitalization, and first all‐cause hospitalization among low‐risk CHA~2~DS~2~VASc groups. Event rates stratified by the use of OAC versus no antithrombotic therapy are shown in (Table [4](#jah33418-tbl-0004){ref-type="table"}). For patients with a CHA~2~DS~2~VASc score of 0,1, and females with a CHA~2~DS~2~VASc=2, event rates for stroke/TIA/thromboembolism were ≤1.5 events per 100 patient‐years, with or without OAC. All‐cause mortality for the lowest‐risk groups was low and comparable for patients with or without OAC use. For patients with a CHA~2~DS~2~VASc ≥2, OAC use demonstrated a lower event rate with respect to thromboembolic event rates. A similar trend was noted with respect to all‐cause mortality.

###### 

Adjusted Rates of Major Outcomes Across CHA~2~DS~2~VASc Groups

  Outcome                                                                   CHA~2~DS~2~VASc=0[a](#jah33418-note-0006){ref-type="fn"}   CHA~2~DS~2~VASc=1[a](#jah33418-note-0006){ref-type="fn"}   Female With Additional Risk Factor[a](#jah33418-note-0006){ref-type="fn"}   CHA~2~DS~2~VASc≥2[a](#jah33418-note-0006){ref-type="fn"}   *P* Value
  ------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------- -----------
  All‐cause death                                                           2 (0.2) \[0.1--1.0\]                                       24 (1.0) \[0.7--1.4\]                                      14 (1.4) \[1.0--2.3\]                                                       1556 (5.7) \[5.4--6.0\]                                    0.45
  Cardiovascular death                                                      1 (0.1) \[0.02--0.9\]                                      5 (0.2) \[0.1--0.5\]                                       3 (0.3) \[0.1--1.0\]                                                        634 (2.3) \[2.2--2.5\]                                     0.67
  First new‐onset‐HF diagnosis                                              6 (0.8) \[0.3--1.7\]                                       15 (0.6) \[0.4--1.0\]                                      6 (0.6) \[0.3--1.3\]                                                        515 (1.9) \[1.8--2.1\]                                     0.38
  First stroke/TIA/systemic embolism                                        0 (0.0)                                                    19 (0.8) \[0.5--1.2\]                                      8 (0.8) \[0.4--1.6\]                                                        459 (1.7) \[1.6--1.9\]                                     0.17
  First major bleeding                                                      11 (1.4) \[0.8--2.5\]                                      23 (0.9) \[0.6--1.4\]                                      24 (2.4) \[1.6--3.6\]                                                       1081 (4.1) \[3.9--4.4\]                                    0.02
  First hospitalization (all cause)                                         168 (26.2) \[23.0--30.5\]                                  470 (24.0) \[22.0--26.3\]                                  230 (29.4) \[25.8--33.4\]                                                   7306 (38.7) \[37.8--40.0\]                                 0.23
  First bleeding hospitalization                                            5 (0.6) \[0.3--1.5\]                                       21 (0.9) \[0.6--1.3\]                                      15 (1.5) \[0.9--2.5\]                                                       937 (3.6) \[3.3--3.8\]                                     0.28
  First cardiovascular hospitalization                                      126 (18.5) \[15.6--22.0\]                                  345 (16.6) \[15.0--18.5\]                                  144 (16.5) \[14.0--19.4\]                                                   4245 (18.8) \[18.3--19.4\]                                 0.03
  First noncardio/nonbleed hospitalization                                  20 (5.1) \[3.8--7.0\]                                      144 (6.2) \[5.2--7.3\]                                     93 (10.0) \[8.1--12.2\]                                                     3897 (16.9) \[16.4--17.4\]                                 0.001
  First cardiovascular death/stroke/TIA/MI/cardiovascular Hospitalization   127 (18.63) \[15.7--22.2\]                                 351 (16.94) \[15.3--19.0\]                                 146 (16.82) \[14.3--19.8\]                                                  4418 (19.7) \[19.1--20.3\]                                 0.03

CHA~2~DS~2~VASc indicates Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus, Stroke, Vascular Disease, Age (65--74 years), Sex; HF, heart failure; MI, myocardial infarction; TIA, transient ischemic attack.

event \# (event \# per 100 patient‐years) \[95% confidence interval\].

###### 

Unadjusted Major Outcomes Across CHA~2~DS~2~VASc Groups Stratified by OAC Use

  Outcome                                                                   CHA~2~DS~2~VASc=0[a](#jah33418-note-0008){ref-type="fn"}   CHA~2~DS~2~VASc=1[a](#jah33418-note-0008){ref-type="fn"}   Female With Additional Risk Factor[a](#jah33418-note-0008){ref-type="fn"}   CHA~2~DS~2~VASc≥2[a](#jah33418-note-0008){ref-type="fn"}                                                                                  
  ------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------- ------------ ------ ----------- ------------ ------ ------------ ------------- ----------
  All‐cause death                                                           1 (1.2)                                                    1 (0.3)                                                    0.30                                                                        2 (1.3)                                                    9 (0.8)      0.42   1 (1.2)     4 (0.8)      0.52   89 (9.6)     665 (5.2)     \<0.0001
  Cardiovascular death                                                      0 (0.0)                                                    1 (0.3)                                                    0.90                                                                        0 (0.0)                                                    3 (0.3)      1.00   0 (0.0)     1 (0.2)      0.73   33 (3.6)     260 (2.0)     0.002
  First new‐onset‐HF diagnosis                                              0 (0.0)                                                    5 (1.6)                                                    0.60                                                                        1 (0.6)                                                    7 (0.7)      0.73   0 (0.0)     2 (0.4)      1.00   22 (2.4)     232 (1.8)     0.17
  First stroke/TIA/systemic embolism                                        0 (0.0)                                                    0 (0.0)                                                    --                                                                          1 (0.6)                                                    9 (0.8)      0.94   0 (0.0)     7 (1.5)      0.60   15 (1.6)     189 (1.5)     0.63
  First major bleeding                                                      2 (2.4)                                                    5 (1.6)                                                    0.50                                                                        0 (0.0)                                                    8 (0.8)      0.56   4 (5.2)     9 (2.0)      0.06   44 (5.0)     446 (3.6)     0.03
  First hospitalization (all cause)                                         10 (13.0)                                                  76 (31.4)                                                  0.03                                                                        28 (21.5)                                                  214 (25.7)   0.56   18 (31.0)   110 (31.0)   0.91   244 (36.6)   3252 (35.4)   0.53
  First bleeding hospitalization                                            1 (1.2)                                                    3 (1.0)                                                    0.53                                                                        0 (0.0)                                                    9 (0.8)      0.50   3 (3.9)     6 (1.3)      0.10   33 (3.7)     400 (3.2)     0.42
  First cardiovascular hospitalization                                      4 (5.1)                                                    55 (21.1)                                                  0.02                                                                        18 (13.1)                                                  153 (17.1)   0.44   8 (11.3)    73 (18.3)    0.30   132 (16.7)   1820 (16.7)   0.93
  First noncardio/nonbleed Hospitalization                                  5 (6.3)                                                    17 (5.5)                                                   0.84                                                                        13 (8.7)                                                   67 (6.7)     0.30   9 (13.0)    46 (11.0)    0.46   144 (18.3)   1769 (16.1)   0.13
  First cardiovascular death/stroke/TIA/MI/cardiovascular hospitalization   4 (5.1)                                                    55 (21.1)                                                  0.02                                                                        18 (13.2)                                                  156 (17.5)   0.40   8 (11.3)    75 (19.0)    0.26   134 (17.0)   1902 (17.6)   0.78

CHA~2~DS~2~VASc indicates Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus, Stroke, Vascular Disease, Age (65--74 years), Sex; HF, heart failure; MI, myocardial infarction; OAC, oral anticoagulation; TIA, transient ischemic attack.

event \# (event \# per 100 patient‐years).

CHA~2~DS~2~VASc=1 {#jah33418-sec-0017}
-----------------

The supplemental materials show the characteristics and outcomes for CHA~2~DS~2~VASc=1 patients. Hypertension was the most common risk factor (N=855/1589 patients, 53.8%) in the combined ORBIT‐AF cohort (Table [S1](#jah33418-sup-0001){ref-type="supplementary-material"}). Among CHA~2~DS~2~VASc=1 patients, females (N=253/1589) were more likely to not be treated with an antiplatelet or OAC (15% vs. 6.0%, *P*\<0.0001), more likely to be treated with aspirin at baseline (49% vs. 36%, *P*\<0.0001), and less likely to be treated with any OAC (49% vs. 74%, *P*\<0.0001) compared with males (Table [S2](#jah33418-sup-0001){ref-type="supplementary-material"}). Thromboembolic event rates (TIA, stroke, or systemic embolism) among men and women were \<1 event per 100 patient‐years: 0.8 per 100 patient‐years for CHA~2~DS~2~VASc=1, and 0.8 per 100 patient‐years for both sexes. All‐cause mortality was low among both males (1.0 per 100 patient‐years) and females (0). Major adverse cardiovascular and neurologic events were highest in females with a CHA~2~DS~2~VASc=1 (18.0 vs. 16.0 per 100 patient‐years) (Table [S3](#jah33418-sup-0001){ref-type="supplementary-material"}). Stratifying outcomes by the use of OAC versus no antithrombotic therapy demonstrated lower all‐cause mortality with OAC treatment (0.8 vs. 1.3 events per 100 patient‐years). Stroke rates were \<1 event per 100 patient‐years irrespective of treatment with OAC (Table [4](#jah33418-tbl-0004){ref-type="table"}). Major outcomes for age 65 to 75 years CHA~2~DS~2~VASc=1 patients in the combined ORBIT‐AF and ORBIT‐AF II cohorts are shown in Table [S4](#jah33418-sup-0001){ref-type="supplementary-material"}.

Patients With New‐Onset AF {#jah33418-sec-0018}
--------------------------

A sensitivity analysis was performed in patients with new‐onset AF only, in order to ascertain whether incident or prevalent AF altered treatment patterns with respect to stroke prevention and overall outcomes. Patients with new‐onset AF accounted for 26% (N=4783/18 398) of patients in the overall cohort. Overall, CHA~2~DS~2~VASc 0‐1 or females with a CHA~2~DS~2~VASc score=2 accounted for 19.8% (N=936/4738) of all patients with new‐onset AF. Any OAC use among patients with low‐risk new‐onset AF demonstrated a similar trend compared with the overall analysis, with increasing OAC use paralleling increasing CHA~2~DS~2~VASc score (Table [S5](#jah33418-sup-0001){ref-type="supplementary-material"}).

Similar to the overall cohort, in patients with new‐onset AF, thromboembolic event rates (TIA, stroke, or systemic embolism) increased with CHA~2~DS~2~VASc scores: zero per 100 patient‐years for CHA~2~DS~2~VASc=0, 0.7 per 100 patient‐years in CHA~2~DS~2~VASc=1, 1.2 per 100 patient‐years in females with a CHA~2~DS~2~VASc score=2, and 1.6 per 100 patient‐years for patients with a CHA~2~DS~2~VASc ≥2. All‐cause mortality was low among low‐risk CHA~2~DS~2~VASc groups but highest among patients with a CHA~2~DS~2~VASc ≥2 (4.6 per 100 patient‐years) (Table [S6](#jah33418-sup-0001){ref-type="supplementary-material"}). Event rates stratified by the use of OAC versus no antithrombotic therapy in patients with new‐onset AF are shown in Table [S7](#jah33418-sup-0001){ref-type="supplementary-material"}. Rates of thromboembolism were low among all low‐risk groups irrespective of OAC use, except for females with a CHA~2~DS~2~VASc=2 treated with OAC with an event rate of 2.2 per 100 patient‐years.

Discussion {#jah33418-sec-0019}
==========

Prevention of thromboembolism is of paramount importance in the care of patients with AF. However, the optimal treatment strategy for patients with AF and a low‐risk thromboembolism is unknown. This analysis of low‐risk patients in nationwide clinical practice yields several important findings. First, many patients at low risk for embolic events as defined by the CHA~2~DS~2~VASc score were on systemic OAC. Second, aspirin use was very high in low‐risk groups, even in those already treated with OACs at baseline. Third, outcomes were worse with increasing risk as reflected by the CHA~2~DS~2~VASc score. However, the risk of thromboembolism did not materially differ between patients with CHA~2~DS~2~VASc=1 and females with a CHA~2~DS~2~VASc score=2. In addition, several notable outliers were noted including the following: a relatively high rate of hospitalizations was documented in low‐risk patients, higher risk of stroke/TIA, and the composite outcome (cardiovascular death, stroke/TIA, myocardial infarction, and cardiovascular hospitalization) among females with an additional stroke risk factor taking OAC versus no OAC.

Finally, systemic OAC was associated with lower rates of all‐cause mortality, cardiovascular death, and first stroke/TIA among patients with a CHA~2~DS~2~VASc score ≥2.

Currently, the AHA/ACC/HRS guidelines for the management of AF recommend a risk‐based assessment for stroke prevention therapy. For patients with a CHA~2~DS~2~VASc=1, guideline recommendations are equivocal stating that no therapy, ASA alone, or OAC are all reasonable options (Class IIB; Level of Evidence C).[10](#jah33418-bib-0010){ref-type="ref"} In addition, there are few data on the risk of stroke/systemic embolism in females with a CHA~2~DS~2~VASc=2 and few descriptions of contemporary treatment patterns in US clinical practice. Notably, international estimates of risk in this important subgroup have been variable, often with marked differences in absolute risk.[17](#jah33418-bib-0017){ref-type="ref"}, [18](#jah33418-bib-0018){ref-type="ref"}

Prior studies using the CHA~2~DS~2~VASc stratification tool have produced differing conclusions regarding the role of OAC in patients with an additional risk factor for stroke/systemic embolism.[19](#jah33418-bib-0019){ref-type="ref"} Lip and colleagues in a large Danish cohort of patients with AF demonstrated that in untreated patients with 1 additional stroke risk factor (CHA~2~DS~2~VASc=1 \[male\],=2 \[female\]), strokes rates increased 3‐fold compared with untreated low‐risk patients (CHA~2~DS~2~VASc=0 \[male\], =1 \[female\]).[20](#jah33418-bib-0020){ref-type="ref"} Similarly, Chao and colleagues in a large Taiwanese cohort of patients with AF demonstrated that untreated patients with 1 additional risk factor for stroke derived a benefit from OAC given their increased risk of ischemic stroke.[21](#jah33418-bib-0021){ref-type="ref"} Conversely, Friberg and colleagues, in a large Swedish cohort, showed that untreated patients with 1 additional stroke risk factor had lower risk of ischemic stroke than previously reported and that the use of OAC in this group provided no associated benefit.[18](#jah33418-bib-0018){ref-type="ref"}

Our study is derived from 2 large cohorts of patients with AF from the United States, many of whom were treated with OAC. In comparison to the results from many of the European registries, our data among patients with both new‐onset AF and prevalent AF suggest that there is a very low risk of thromboembolic events (stroke/TIA/systemic embolism) among patients with an additional risk factor for stroke. Some of the low event rates may be attributed to the moderate use of OAC with warfarin or direct OACs at baseline, including among patients with a CHA~2~DS~2~VASc=0. However, there were no major differences in event rates in those low‐risk patients who were and were not receiving OAC. The fact that up to 40% of the lowest risk patients with a CHA~2~DS~2~VASc=0 were on antiplatelet therapy with aspirin and \>60% of all low‐risk patients were on OAC underscores several important points: (1) improved implementation of evidence‐based guidelines regarding risk stratification for stroke and OAC administration is needed among low‐risk patients as our results are in discord with the current AHA/ACC guideline recommendations for stroke prevention in patients with AF with the lowest risk for stroke; (2) the presence of AF and not the overall thromboembolic risk profile may be a primary driver of the administration of therapy for stroke prevention; and (3) practice patterns vary significantly among US physicians, reflecting the poor adherence and lack of consistent application to the guidelines. It is important to note that many low‐risk patients, who are younger and more likely to have symptomatic AF, have a class I recommendation for OAC surrounding cardioversion or ablation procedures, which may explain the increased use of OAC. In addition, the relatively high rate of hospitalization in patients at low risk for stroke suggests that these patients have substantial morbidity and a mortality rate that is low but not negligible. While our results are in alignment with recommendations from the AHA/ACC/HRS guidelines for the management of AF for patients with 1 additional stroke risk factor, the European guidelines favor treatment in patients with 1 nonsex risk factor.[12](#jah33418-bib-0012){ref-type="ref"}

The impact of sex on major outcomes in the ORBIT‐AF and ORBIT‐AF II registries suggest that females have an overall increased risk profile with respect to hospitalizations, bleeding, and mortality. Although the cause of the differential risk is unclear, our findings suggest that female patients with an additional risk factor for stroke have higher risk of adverse events. Future studies are needed to clarify the impact of sex in low‐risk CHA~2~DS~2~VASc populations. Moreoever, disease‐modifying therapy, potentially with angiotensin‐converting enzyme inhibition or other renin--angiotensin--aldosterone system antagonism, may also provide benefit over the long‐term in women with additional risk factors for stroke given their increased risk of incident heart failure. This hypothesis should be tested in a clinical trial.

Limitations {#jah33418-sec-0020}
-----------

Several limitations need to be acknowledged when considering these data. First, both the ORBIT‐AF and ORBIT‐AF II study populations were derived from practices participating in a voluntary US registry and may not be representative of all patients with AF in general. Second, the overall low event rate with respect to major outcomes precludes multivariate adjustment in this analysis. Because of the higher incidence of non‐CHA~2~DS~2~VASc risk factors for death such as cancer and chronic obstructive pulmonary disease, we cannot conclude that the risk factors in the CHA~2~DS~2~VASc risk score are solely responsible for the higher rates of hospitalization and death. In addition, the absolute risk of major outcomes without treatment with antiplatelet or anticoagulants at baseline could not be determined. Many of our low‐risk patients had a very high rate of OAC use, which may have confounded our result of no differences in stroke/systemic embolism CHA~2~DS~2~VASc=1 and females with a CHA~2~DS~2~VASc score. Additionally, selection bias may have led to selection of sites and patients, which were more likely to be on OAC. Finally, our rates of ischemic events, including stroke, were a combined end point including both TIA and systemic embolism. Several large retrospective registries have suggested that a more "diverse" end point can lead to an overestimation of risk, leading to higher rates of treatment with OAC and potentially increased risk versus benefit.

Conclusions {#jah33418-sec-0021}
===========

Although the absolute risk of death and stroke/TIA are low among CHA~2~DS~2~VASc=0‐1 and females with a CHA~2~DS~2~VASc=2, females with 1 additional risk factor have higher risk of major cardiovascular outcomes and all‐cause mortality among low‐risk CHA~2~DS~2~VASc groups. Despite the absence of a Class I recommendation according to the AHA/ACC/HRS AF guidelines,[22](#jah33418-bib-0022){ref-type="ref"} in contemporary US clinical practice, 60% to 72% of low‐risk patients with AF receive OAC. Randomized trials are needed to clarify the optimal anticoagulation strategy in patients with CHA~2~DS~2~VASc=0, 1 or women with 1 additional risk factor.
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[^1]: A complete list of the ORBIT AF and ORBIT AF II Investigators is provided in the Supplemental Material.
